Table 1 Immunohistochemical (IHC) staining characteristics in primary urinary bladder adenocarcinoma, urothelial carcinoma with glandular differentiation, secondary colorectal adenocarcinoma, and primary colorectal adenocarcinoma

	Primary urinary bladder adenocarcinoma (n=25)					Urothelial carcinoma with glandular differentiation (n=11)										Secondary involvement of bladder by colorectal carcinoma (n=25)					Primary colorectal carcinoma (n=22)
						Urothelial component					Glandular component
	IHC scoring ^a					IHC scoring					IHC scoring					IHC scoring					IHC scoring
	0	1+	2+	3+	Total pos	0	1+	2+	3+	Total pos	0	1+	2+	3+	Total pos	0	1+	2+	3+	Total pos	0	1+	2+	3+	Total pos
Cadherin-17 (membranous)	2	2	5	16	23 (92%)	11	0	0	0	0	11	0	0	0	0	2	0	6	17	23 (92%)	1	0	2	19	21 (95%)
GATA3 (nuclear)	25	0	0	0	0	9	0	0	2	2 (18%)	10	0	1	0	1 (9%)	25	0	0	0	0	22	0	0	0	0
p63 (nuclear)	25	0	0	0	0	3	0	1	7	8 (73%)	11	0	0	0	0	25	0	0	0	0	22	0	0	0	0
β-Catenin (membranous)	2	0	1	22	23 (92%)	0	0	0	11	11 (100%)	0	0	0	11	11 (100%)	23	0	0	2	2 (8%)	21	0	1	0	1 (5%)
β-Catenin (nuclear)	23	0	0	2	2 (8%)	11	0	0	0	0	11	0	0	0	0	2	0	4	19	23 (92%)	1	0	0	21	21 (95%)

^aIHC scoring: 0 (negative)=0% tumor cell positivity; 1+ (focal)=1–10% tumor cell positivity; 2+ (moderate)=11–50% tumor cell positivity; and 3+ (diffuse)=>50% tumor cell positivity. Pos, positive. Expression of cadherin-17 showed a statistically significant difference when pure adenocarcinoma (colorectal or primary urinary bladder) was compared with urothelial carcinoma with glandular differentiation (P<0.001). Statistically significant differences were also detected in the staining pattern for β-catenin (nuclear vs cytoplasmic and membranous) in colorectal carcinomas when compared with urothelial carcinomas and primary urinary bladder adenocarcinomas (P<0.001). p63 labeled only the urothelial component of urothelial carcinoma with glandular differentiation (P<0.001).

Search